What is the history of PPIs?

Omeprazole was the first PPI to hit the market in 1988, followed by Lansoprazole, which came to the US in 1995. Decades later, more is known about the risks associated with taking these medications. The following timeline outlines new information about the risks associated with the drugs:

  • May 25, 2010: The FDA published information regarding the link between long-term use of PPIs and an increased risk for fracture of the spine, wrist and hip.
  • March 2, 2011: The FDA reports that low magnesium levels may be associated with long-term use of PPIs.
  • March 22, 2011: The FDA determines a warning label regarding the increased risk of fracture is unnecessary.
  • February 8, 2012: The FDA informed the public that PPIs could increase the risk for Clostridium difficile, or associated diarrhea.
  • December 11, 2013: A JAMA study suggests using PPIs may lead to vitamin B12 deficiency.
  • November 2014: The FDA requires a warning on some packages about associated diarrhea and interactions with other drugs.
  • January 11, 2016: A JAMA Internal Medicine study finds PPI use is associated with a higher risk of chronic kidney disease.
  • April 2016: A JAMA Neurology study suggests PPI use could increase the risk for dementia.
  • April 16, 2016: A CMAJ Open study finds adults aged 66+ who take PPIs have an increased risk of acute kidney injury and AIN.